Clinical trials: Relapsed Solid Tumor
- Condition Relapsed Solid Tumor
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Adenocarcinoma, Neoplasms
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors.
- Trial name
- NCT00106353
- Testing
- Torisel
- Where
- 30 sites in United States, Canada and 5 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Malignant Neoplasm
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: Hepatoblastoma is a common liver cancer in babies and very young children RMS is a cancer…
- Trial name
- NCT06941272
- Testing
- Patritumab Deruxtecan
- Where
- 64 sites in United States, Australia and 21 more
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Refractory or Relapsed Solid Tumors, Lymphoma
Phase I/II Study of Avelumab in Pediatric Cancer Participants
This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with…
- Trial name
- NCT03451825
- Testing
- Avelumab
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsed or Refractory Solid Tumors
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
The main purpose of this study is to evaluate the antitumor activity and safety of lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration.
- Trial name
- E7080-G000-231 (NCT04447755)
- Testing
- Lenvatinib
- Where
- 49 sites in United States, Argentina and 18 more
- Volunteers
- 127 people
- Sponsor
- Merck Sharp & Dohme LLC
Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer.
- Conditions
- Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma
- Trial name
- NCT06566092
- Testing
- LN-145/LN-144
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Neoplasms
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
- Trial name
- KOURAGE (NCT03967093)
- Testing
- BXQ-350
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Solid Tumors
Study of EZN-2208 Pediatric Patients With Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to pediatric patients with Relapsed or Refractory Solid Tumors.
- Trial name
- NCT01295697
- Testing
- EZN-2208
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Tumors, Hyperuricemia
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor…
- Conditions
- Tumors, Hyperuricemia, Tumor Lysis Syndrome
- Trial name
- NCT00230217
- Testing
- Rasburicase (SR29142)
- Where
- 7 sites in United States
- Volunteers
- 94 people
- Sponsor
- Sanofi
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Relapsed Solid Tumors, Refractory Solid Tumors
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).
- Conditions
- Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC
- Trial name
- NCT04718675
- Testing
- KB-0742
- Where
- 24 sites in United States, Spain and 1 more
- Volunteers
- 135 people
- Sponsor
- Kronos Bio
Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA…
- Conditions
- Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
- Trial name
- NCT04773782
- Testing
- avapritinib
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 29 people
- Sponsor
- Blueprint Medicines Corporation
Neuroblastoma
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors…
- Trial name
- NCT05429502
- Testing
- Topotecan, Temozolomide, Ribociclib
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Neuroblastoma, Osteosarcoma
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
- Conditions
- Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
- Trial name
- NCT03860207
- Testing
- Humanized 3F8 Bispecific Antibody, Blood draw
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y-mAbs Therapeutics
Melanoma, Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: Advanced, which means cancer spread in the body or cannot…
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
- Trial name
- NCT02332668
- Testing
- Pembrolizumab
- Where
- 16 sites in United States, Brazil and 8 more
- Volunteers
- 370 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
- Trial name
- NCT05533697
- Testing
- mRNA-4359, Pembrolizumab, Ipilimumab
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 361 people
- Sponsor
- ModernaTX, Inc.
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Lymphoma, Solid Tumor (Excluding CNS)
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
This is a phase 1, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and antitumor activity of pixantrone in pediatric patients with relapsed or refractory solid tumors (excluding those with CNS tumors)…
- Trial name
- NCT02800889
- Testing
- Pixantrone
- Where
- United States
- Sponsor
- CTI BioPharma